Clinical Trial Update: IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients [Phase 1]

View source ↗

Summary

Phase 1 trial of the personalized neoantigen vaccine IVAC-RCC-001 added to standard-of-care checkpoint inhibitor therapy for advanced renal cell carcinoma has b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• IVAC-RCC-001

Snippet

Sponsor: SLK Kliniken Heilbronn GmbH | Conditions: Advanced Renal Cell Carcinoma | Phase 1 | Status: TERMINATED